Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Additive diagnostic value of prostate specific membrane antigen (PSMA) positron emission tomography (PET) and micro ribonucleic acid (miRNA) to multiparametric magnetic resonance imaging (mpMRI) in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer

Trial Profile

Additive diagnostic value of prostate specific membrane antigen (PSMA) positron emission tomography (PET) and micro ribonucleic acid (miRNA) to multiparametric magnetic resonance imaging (mpMRI) in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs 68-Ga-PSMA-617 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms PRIMARY
  • Most Recent Events

    • 09 Oct 2018 New trial record
    • 05 Oct 2018 Recruitment is expected to complete on 18 Feb 2019 according to Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top